Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹16 Cr
Revenue (TTM)
₹1 Cr
Net Profit (TTM)
₹0 Cr
ROE
0.4 %
ROCE
0.4 %
P/E Ratio
41.1
P/B Ratio
4
Industry P/E
101.25
EV/EBITDA
39.9
Div. Yield
0 %
Debt to Equity
0
Book Value
₹13
EPS
₹1.3
Face value
10
Shares outstanding
3,054,500
CFO
₹-1.42 Cr
EBITDA
₹0.86 Cr
Net Profit
₹0.24 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Genomic Biotech
| -34.9 | -17.9 | -14.6 | 47.5 | 18.9 | 38.8 | -- |
|
BSE Healthcare
| -5.9 | 0.5 | 7.3 | 18.6 | 22.8 | 22.3 | 9.5 |
|
BSE Small Cap
| -6.0 | 4.8 | 12.4 | 7.4 | 25.0 | 37.4 | 16.5 |
|
Company
|
2024
|
|---|---|
|
Genomic Biotech
| 103.4 |
|
BSE Small Cap
| 29.0 |
|
BSE Healthcare
| 43.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Genomic Biotech
|
52.1 | 15.9 | 0.6 | 0.4 | 65.5 | 10.5 | 41.1 | 4.0 |
| 252.1 | 3,954.9 | 2,711.5 | 3.2 | 6.5 | 0.5 | -- | 0.7 | |
| 116.9 | 416.9 | 132.8 | 3.8 | 5.7 | 4.9 | 101.3 | 4.1 | |
| 246.7 | 11,181.8 | 2,622.8 | 382.6 | 17.0 | 16 | 29.4 | 4.5 | |
| 30.7 | 923.7 | 1,006.4 | 46.5 | 8.0 | 11 | 19.9 | 2.1 | |
| 5,009.8 | 11,544.1 | 667.6 | 168.3 | 37.0 | 82.8 | 68.6 | 35.8 | |
| 9.6 | 144.7 | 13.2 | -68.3 | -175.4 | -- | -- | -17.5 | |
| 38.0 | 68.1 | 46.7 | 7.3 | 24.6 | 10.6 | 9.4 | 0.9 |
No Review & Analysis are available.
Wholesale of agricultural raw materials and live animals
Incorporated
1994
Chairman
--
Managing Director
Yogesh Agrawal
Headquarters
Jhajjar Dist, Haryana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Genomic Valley Biotech Ltd stood at ₹ 4 Cr as on 31-Dec-24
The share price of Genomic Valley Biotech Ltd is ₹52.06 (BSE) as of 23-May-2025 IST. Genomic Valley Biotech Ltd has given a return of 18.86% in the last 3 years.
Genomic Valley Biotech Ltd has a market capitalisation of ₹ 16 Cr as on 23-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Genomic Valley Biotech Ltd is 4.00 times as on 23-May-2025, a 330% premium to its peers’ median range of 0.93 times.
The P/E ratio of Genomic Valley Biotech Ltd is 41.09 times as on 23-May-2025, a 59% discount to its peers’ median range of 101.25 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Genomic Valley Biotech Ltd and enter the required number of quantities and click on buy to purchase the shares of Genomic Valley Biotech Ltd.
Wholesale of agricultural raw materials and live animals
The promoter of Genomic Valley Biotech Ltd is Yogesh Agrawal. Yogesh Agrawal owns 46.72 per cent of the total equity. The chairman of the company is , and the managing director is Yogesh Agrawal..
There is no promoter pledging in Genomic Valley Biotech Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
3,955
|
|
|
417
|
|
|
145
|
|
|
68
|
|
|
11,544
|
|
|
11,182
|
|
|
3,955
|
|
|
924
|
|
|
417
|
| Genomic Valley Biotech Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
10.52
|
|
Operating margin(%)
|
65.52
|
|
Net Margin(%)
|
65.93
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Genomic Valley Biotech Ltd was ₹0 Cr.
₹-1.06
(
